Cumberland Pharmaceuticals Inc.

Jean W. Marstiller directs the Company's administrative operations, site services and information systems. She also serves as the Company's corporate secretary. Ms. Marstiller held similar responsibilities for ten years at Therapeutic Antibodies Inc., a biopharmaceutical company. Previously, Ms. Marstiller worked at Brown-Forman Corporation, where she rose through management-level positions in the areas of finance, direct mail and sales.

Martin E. Cearnal, Director. Mr. Cearnal has served as a member of our board of directors since 2004. He is the former President and Chief Executive Officer of Physicians World, which became the largest provider of continuing medical education during his tenure from 1985 to 2000. Physicians World was acquired by Thomson Healthcare in 2000. Mr. Cearnal served as President of Thomson Physicians World from 2000 to 2003, and Executive Vice President-Chief Strategy Officer for Thomson Medical Education from 2003 through 2005. Since 2006, he has been Executive Vice President-Chief Strategy Officer for Jobson Medical Information. Mr. Cearnal has 40 years experience in the Healthcare industry Management

J. William Hix is responsible for all sales and marketing efforts at Cumberland. Mr. Hix joined the Company in 2004 to form and manage the national sales force promoting the acute care product line to hospitals, poison control centers and physicians. He was also instrumental in the design and implementation of Cumberland's field sales force which is responsible for promoting Company products in the gastroenterology market. Mr. Hix brings significant industry experience to the Company, having spent thirty years at Novartis/CIBA-GEIGY Pharmaceutical Corporation. There his responsibilities ranged from sales operations, planning and promotion to marketing support and regulatory compliance.

Leo Pavliv, R.Ph. has over twenty years of experience developing pharmaceutical and biological products. Beginning his career at Parke-Davis, he has worked with both large pharmaceutical and small development biotechnology companies in various scientific and management positions. Most recently, he served as Vice President of Pharmaceutical Development at Cato Research, a full-service contract research and development organization. Mr. Pavliv has authored and reviewed numerous regulatory submissions to the FDA and foreign regulatory agencies, as well as several articles, a book chapter and presentations on a variety of chemistry, manufacturing and controls topics at industry meetings.

Elizabeth C. Gerken coordinates business development activities and is engaged in the identification of product opportunities, the process of due diligence and the negotiation of deal terms for Cumberland's agreements. Ms. Gerken previously spent eight years with Eli Lilly and Company, including management roles in Strategic Planning, Brand Management, Sales Management, and Business Development.

Gordon R. Bernard, M.D., is Chief of Pulmonary Service and Professor of Medicine at Vanderbilt University School of Medicine. In addition, he is Medical Director for the Institutional Review Board. Dr. Bernard is a leader in the area of cardiopulmonary medicine and sepsis research and he has published more than 100 peer-reviewed articles on these topics. He chairs the Steering Committee for NHLBI Acute Respiratory Distress Syndrome Clinical Trials Network. Dr. Bernard received his M.D. degree from Louisiana State University. He serves on the editorial boards of Clinical Intensive Care, Journal of Critical Care and Sepsis.

James L. Herman serves as National Accounts Senior Director. He is responsible for all national accounts sales, including wholesalers and chain buying offices, managed care home offices and federal government accounts. Previously he spent five years at Solvay Pharmaceuticals where he served as Director of Managed Care as well as Director of Trade Affairs and Customer Service. Mr. Herman spent eight years at Schwarz Pharma, a worldwide manufacturer of branded drugs, where he held various positions.

Amy D. Rock, Ph.D. is responsible for coordinating FDA submissions, product filings, and clinical trials. Dr. Rock oversees the entire preparation of regulatory submissions, from outlining general strategy to reviewing individual documents. She manages all interactions between Cumberland and the FDA. Dr. Rock has experience with basic research, having published multiple articles in peer-reviewed journals such as The Journal of Immunology, The Journal of Neurosurgery, and Experimental Cell Research.

Bruce J. Kent is responsible for managing that group of sales representatives which promotes Cumberland's gastroenterology product line. Joining the Company in July 2006 to form and launch Cumberland's field sales force, Mr. Kent had 19 years of pharmaceutical industry experience. Beginning his career with CIBA Pharmaceuticals in 1988, he spent 15 years with what is now Novartis Pharmaceuticals, where he held positions of increasing responsibility in sales, sales management, managed healthcare, business analysis, and ebusiness. Prior to joining Cumberland, Mr. Kent was the Executive Director of Sales for Rx Sample Solutions and the head of the Northeast Regional Office from 2004 to 2006. He holds a B.S. from the Pennsylvania State University.

Larry Greer founded Greer Capital Advisors in September 2002 and directed the raise of the S.C.O.U.T. Healthcare Fund, LP as its General Partner. For the previous 13 years he acted as Director of Investments for Dunn Investment Company overseeing a broad range of equity investments and marketable securities portfolio. He was directly involved with management, operational oversight, strategic planning, capitalization events and negotiations regarding industry collaborations yielding significant results. Three portfolio companies completed initial public offerings, three were successfully acquired and the marketable securities portfolio returned well above the DJIA and S&P 500 for the same period while under his management. Prior to entering the investments field, Dr. Greer practiced Dentistry in Birmingham for 14 years. Dr. Greer serves on the Boards of many of the Fund's portfolio companies in addition to the Biotechnology Association of Alabama and several start-up tech transfer companies. Dr. Greer received his MBA and DDS from Emory University and his BS from Tulane University.

Dr. Robert G. Edwards brings extensive medical, business and international experience to the Company, coordinating International Business Development activities. Previously he was Chairman and Managing Director of Therapeutic Antibodies Inc.'s Australasian subsidiary, overseeing operations in Australia, New Zealand and Southeast Asia. Dr. Edwards' distinguished career includes having served as Deputy Director of the Institute for Medical & Veterinary Science in South Australia, President of the Royal College of Pathologists of Australasia, and member of the Australian National Health & Medical Research Council.